Navigation Links
Aviir Laboratories Announce National Agreement With MultiPlan

IRVINE, Calif., April 25, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory announced today that it has entered into a contractual agreement with MultiPlan, Inc. for ancillary diagnostics laboratory testing. The agreement includes Aviir's participation in the MultiPlan, PHCS and PHCS Savility Networks.

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests.

Aviir's agreement with MultiPlan will give MultiPlan's participating providers and its clients' members access to Aviir's tests. Approximately 900,000 providers participate in MultiPlan's provider networks and an estimated 57 million consumers have access to one or more of these networks.

"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir. "Our agreement with MultiPlan will help ensure more doctors and therefore patients have access to the tools that can provide the accurate assessment."

"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reduce their risk of heart attacks, and decrease the overall cost of care." Dr. Harrington added.

Learn more about Aviir at

Learn more about MultiPlan at

For more information:
Dina Scaglione
(949) 910-9401

SOURCE Aviir Diagnostic Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. MO BIO Laboratories, Inc. Launches the PowerMicrobiome™ RNA Isolation Kit
3. ARUP Laboratories Announces Creation of Business Innovations Division
4. EMD Millipore Partners with Charles River Laboratories for Improved Viral Clearance Studies
5. John Saltamartine to Lead Operations as VR Laboratories Chief Operating Officer
6. ARUP Laboratories Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology
7. IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri
8. VetNostic Laboratories® Announces New Testing for Dog Breeds
9. Access Medical Laboratories, Inc. to Celebrate Grand Opening of New Laboratory Headquarters in Jupiter, Florida
10. Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories
11. MO BIO Laboratories, Inc. Launches the RTS DNase™ Kit
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):